3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

6 Customer Reviews

  • granulosa cells (GCs) with 24 h of melatonin (10 μM) treatment were rinsed in PBS, and then exposed to H2O2 (200 μM) for 2 h. The autophagy inhibitor 3-MA (10 mM), or the apoptosis inhibitor Z-VAD-FMK (50 μM) were added 1 h prior to H2O2 incubation. Cell viability was determined using the CCK-8 assay. Data represent mean ± S.E; n = 3 in each group. *P < 0.05 (**P < 0.01) vs. vehicle group at 0 h. # Represents P < 0.05 (## Represents P < 0.01) vs. H2O2-only-treated cells. & Represents P > 0.05 vs. H2O2-only-treated cells. N, not significant, P > 0.05. δ Represents P < 0.05 (δδ Represents P < 0.01) vs. Z-VAD-FMK-treated cells.

    Redox Biol, 2018, 18:138-157. 3-Methyladenine (3-MA) purchased from Selleck.

    MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

  • Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

    PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

  • After getting treated with 10 μM compound C for indicated time periods with or without 50 μM 3-MA (C) pre-treatment for 1 h, the levels of indicated proteins in QBC939 and RBE cells were analyzed using Western blot.

    J Cell Biochem, 2017, 119(7):5538-5550. 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NV3SSHVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\lNWxbO22P MVmybC=> M1;4dGROW09? NUXtdZlRemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= M1XlflI2PzF4NU[x
A549  NFm4WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnpN41O M3HrVFJp M3HGTWROW09? Mn3hdoVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? M3nYT|I2PzF4NU[x
95D NF\jNIZCeG:ydH;zbZMhSXO|YYm= NWm2NmRwPW2P NVTRW49DOmh? NX:wRlI6TE2VTx?= MnPlbY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq NF\yW|MzPTdzNkW2NS=>
A549  MYXBdI9xfG:|aYOgRZN{[Xl? MkDwOY1O Mkm1Nog> M4D4ZWROW09? Mm\2bY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq NU\o[YVJOjV5MU[1OlE>
NBL-W-S  NVWyZ|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonKNY1O NFP4bnU3cA>? M3THb4VvcGGwY3XzJGdCVlRvNkGgeI95cWOrdIm= MV2yOVMzOzJ{Mh?=
NBL-W-S  NFv0VJhCeG:ydH;zbZMhSXO|YYm= Mn;XNY1O M1\nSFZp M1j3[Ylv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCVlRvNkG= MoPWNlU{OjN{MkK=
A2780cp  M1L1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC2S|MydU1? NHn3ZWkycA>? M{LubYlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp Mn7sNlU{OjJ4OUS=
A549  NU[0[FZVTnWwY4Tpc44hSXO|YYm= Ml[3OY1O NGXoeXIzcA>? MUXzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= M4rme|I2Ojh3NkK4
H157 NH:4RYZHfW6ldHnvckBCe3OjeR?= MVW1cW0> MYqybC=> M4rISpN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> MWmyOVI5PTZ{OB?=
MDR MXLBdI9xfG:|aYOgRZN{[Xl? MojqNVBuVQ>? M33pcVZp NXLwSllne3S{ZX7neIhmdnNidHjlJJBwf2W{IH;mJIFvfGmlYX7j[ZIh\HK3Z4O= MkXzNlUxOTl5MEG=
HT-29  MV3BdI9xfG:|aYOgRZN{[Xl? MnrENY1O MUi0PIg> MUPEUXNQ NFy3ZWdmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NFPOXHUzPDh2MkG1PC=>
Microglia  MV;BdI9xfG:|aYOgRZN{[Xl? NVu2dGxPPW2P NXTMbHRHOjSq MUjk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= Mnn0NlQ5OTh4MEG=
A2780cp NXHIUGppSXCxcITvd4l{KEG|c3H5 MoPpNk42dU1? NHiyXpUycA>? M2HSPYRlUDKR MlPa[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M3;4e|I1QDF5OUS2
HepG2 NH;mfo1HfW6ldHnvckBCe3OjeR?= NXPRTpJbPW2P M1v6eFRp M{DzbIlv[3KnYYPld{BJVCC{ZXzlZZNm MlTONlQ4OTN3OEe=
A549 NWXXO2JTSXCxcITvd4l{KEG|c3H5 NH6yco82dU1? NYL4[mhyPDiq MkLF[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>? MXWyOFcxPjNyMx?=
U2OS M3;YW2Fxd3C2b4Ppd{BCe3OjeR?= MnjoNVBuVQ>? M3q4[FI1cA>? MX;pcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> Mkn5NlQ3OzlyMUO=
Saos-2 NEHpeZpCeG:ydH;zbZMhSXO|YYm= NYnRc2x5OTCvTR?= MVqyOIg> MWfpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> NELZUWYzPDZ|OUCxNy=>
A549 MV7BdI9xfG:|aYOgRZN{[Xl? M3TMd|ExdU1? MYW0PIg> MX;hZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ NIXjVXAzPDZ{NkeyNi=>
HCT116  NEDSV5FCeG:ydH;zbZMhSXO|YYm= Mke2OY1O NEDYUYYzPGh? NVXJUXRo\W6qYX7j[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIFxcWenbnnu NEPK[HEzPDZ{NkWyNi=>
HGC-27 MVnGeY5kfGmxbjDBd5NigQ>? M3fuVlExdU1? MX:xbC=> NF:zcWZqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhdG:|czDifUBTSURyMEGgc5IhVUtvMkKwOi=> NGTGT5QzPDRzNkO0PS=>
U2OS  M3fOWWZ2dmO2aX;uJGF{e2G7 NUTJS5hoOC53L{HtUS=> MW[0PIg> MnnGbY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> M2jLW|I1OzV6M{Sy
MG-63 MlPsSpVv[3Srb36gRZN{[Xl? MmLRNE42NzGvTR?= NH71VlY1QGh? NVXRUoxqcW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MnfXNlQ{PTh|NEK=
MG-63 MYXBdI9xfG:|aYOgRZN{[Xl? M1v2[lAvPS9zbV2= MnnqN|Jp MV;lcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NXH4emR2OjR|NUizOFI>
MG-63 M{PQWWFxd3C2b4Ppd{BCe3OjeR?= NXj4RXpOOTCvTR?= M1fmZlEzcA>? NGXYN5lmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? M1jaUlI1OzV6M{Cx
NTUB1 NGfxRWFCeG:ydH;zbZMhSXO|YYm= M2DXdlVuVQ>? NWPB[GJXOS53aB?= MV3wc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM> Mmq0NlQ{PDlzN{[=
T24 MmHIRZBweHSxc3nzJGF{e2G7 NWfBT2k5PW2P Mln0NU42cA>? MlHPdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ Mnu4NlQ{PDlzN{[=
SGC-7901  M135ZmFxd3C2b4Ppd{BCe3OjeR?= M3i1WVJuVQ>? NV[5c4N7OWh? MmXVbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MoG4NlQ{OjF|NEC=
SMMC-7721 Mn21RZBweHSxc3nzJGF{e2G7 MlTwNo1O NV7h[2s4OWh? MnL4bY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MoDPNlQ{OjF|NEC=
ECSCs  NF\GUGJCeG:ydH;zbZMhSXO|YYm= MX:xNI1O MnS0OIg> MXjk[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz MYiyOFMyQTFyOR?=
MCF-7  NUXCR4F[TnWwY4Tpc44hSXO|YYm= MXSxNI1O NXPlbHV2OjSq MUjpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JIRzfWe| NWDueZhjOjR|MUW1O|g>
UOK257 NYDxbHVwSXCxcITvd4l{KEG|c3H5 M{TVd|VuVQ>? Ml\NN4g> NECzbIxmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li MnL1NlQ{ODV4MES=
ACHN-5968 MoXjRZBweHSxc3nzJGF{e2G7 NF70OXo2dU1? MoTwN4g> MWTlcohidmOnczDwZYNtcXSjeHXsMY1m\GmjdHXkJIFxd3C2b4Ppd:Kh MofXNlQ{ODV4MES=
Huh7 NHPtWI9CeG:ydH;zbZMhSXO|YYm= MWKycW0> MXWxNog> NVTVeJZsTE2VTx?= NWXLfpBXcW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> MoXCNlQzQTd|MEC=
Hep3B MXvBdI9xfG:|aYOgRZN{[Xl? MmPyNo1O MYixNog> Mn6zSG1UVw>? NUXL[nVMcW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> MoLINlQzQTd|MEC=
RKO NHjX[oFHfW6ldHnvckBCe3OjeR?= NYLjWINyOm2P NYT3XoJ[OWh? NYDYVHhyTE2VTx?= M3jxOIVvcGGwY3XzJINmdGxiZHXheIgh[nliZ3Xs[IFv[W27Y3nu NW\qcoJMOjR{OUG3O|c>
HepG2 E47 M2O0ZWZ2dmO2aX;uJGF{e2G7 MmXsNk42dU1? M{jsb|Q5cA>? M1:wd4lv[3KnYYPld{B1cGVidH;4bYNqfHlib3[gRWEtKEKVTzygZY5lKEOFbES= M2DZW|I1Ojd|N{O4
LoVo  M3nrOWFxd3C2b4Ppd{BCe3OjeR?= Mkn2OY1O MVO0PIg> M2XI[oVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5? MmXZNlQzODF6MUK=
WiDr MkK4SpVv[3Srb36gRZN{[Xl? M3zyc|ExdU1? MXyxbC=> M3rWTIlvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? M1nrRlI1OTlyNEi5
H1299  MnjXSpVv[3Srb36gRZN{[Xl? NWnh[HlpOTCvTR?= MVG0bC=> NGXJ[2lqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MYmyOFE4OzJyOB?=
H460 M37hPWZ2dmO2aX;uJGF{e2G7 M37uUFExdU1? M2TKS|Rp NWXUSWRvcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? NWTmNHBMOjRzN{OyNFg>
A549 NEe2cGxHfW6ldHnvckBCe3OjeR?= NFHvS20yOG2P MXm0bC=> NU\EWo16cW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= NW\wOmFIOjRzNEK3N|U>
Hep3B M3nSSWFxd3C2b4Ppd{BCe3OjeR?= Mkn2OY1O M2mxblI1cA>? Ml\0ZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz MVKyOFA3PjZ7Mx?=
SMMC-7721 M3XQZmFxd3C2b4Ppd{BCe3OjeR?= NGm0fJI2dU1? NIS5OIEzPGh? NWjDOVN1[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ Mnv6NlQxPjZ4OUO=
HO8910 NIjNdm1CeG:ydH;zbZMhSXO|YYm= MonyNVBuVQ>? MVOxNog> M2f6[oVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq M4WzeVI{QTh|NkGw
MCF7 M3zFS2Z2dmO2aX;uJGF{e2G7 NUHXV2xQPW2P MVmyOIg> M4X2dIlv[3KnYYPld{BEfU9iaX7keYNm\CClZXzsJIRm[XSq MXmyN|k3OjZ{OR?=
HONE-1  MVXGeY5kfGmxbjDBd5NigQ>? Mn;xOY1O MUCxbC=> M2XmTJJmeHKnc4Pld{A3ei2vZXTpZZRm\CCUT2OgdJJw\HWldHnvci=> NUj2PGtROjN6OUKzOVg>
HeLa MYPGeY5kfGmxbjDBd5NigQ>? NYGx[ZJ4OTCvTR?= MYqybC=> MUnzeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> NEfJSG8zOzh4NEezPC=>
HepG2 MoewSpVv[3Srb36gRZN{[Xl? Mn65NVBuVQ>? NV[wdJRuOjSq MYXpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= MXGyN|gyPzB2MB?=
SH-SY5Y NUK4U4RCTnWwY4Tpc44hSXO|YYm= M1TKe|FuVQ>? NF7pNoEzPGh? MWnpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> MYKyN|c1OzF2OB?=
SH-SY5Y MW\BdI9xfG:|aYOgRZN{[Xl? MlzrOY1O M1LrWVFp NHjrNHhi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= NEPWe4QzOzZzOUO5OS=>
PC12  M17p[GZ2dmO2aX;uJGF{e2G7 MlHWNVBuVQ>? NIP0eoUzPGh? MWL3ZZRmeg>? MnvWxsBqdmirYnn0d{BkcHmvb4TyfZB{cW5vbHnr[UBxem:2ZXHzc41idCCjY4Tpeol1gS5? NXXNNoRUOjN4MEO5O|k>
OV2008 MX3BdI9xfG:|aYOgRZN{[Xl? M3rGZVVuVQ>? NGXr[lAzPGh? M4P2NINwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| MV6yN|U6OjJ6MR?=
A2780 NV30VlJZSXCxcITvd4l{KEG|c3H5 Mmi4OY1O MmP2NlRp MVHjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? MlPwNlM2QTJ{OEG=
Saos-2  MV\BdI9xfG:|aYOgRZN{[Xl? MYixcW0> M2\4bFk3cA>? M2LtTolv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY MWKyN|U3OzF5MR?=
1321N1 M{[zZWN6fG:2b4jpZ4l1gSCDc4PhfS=> NUfxfJI{PW2P MojqNlRp MmK1dJJwfGWldIOgZ4VtdCCjZ3HpcpN1KFCFTj3pcoR2[2WmIITvfIlkcXS7 MkWyNlM2OjV{NkW=
SH-SY5Y M1L0e2N6fG:2b4jpZ4l1gSCDc4PhfS=> M3TaZ|VuVQ>? NYjSd5BYOjSq NHPTOIlqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 MYCyN|UzPTJ4NR?=
HT-29  M2nLWGZ2dmO2aX;uJGF{e2G7 NF;pdXQydU1? MWe0PE86Pmh? NYfOe3ZicW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> MXmyN|UxQDJ5Mh?=
OR6 NVfse|gxTnWwY4Tpc44hSXO|YYm= Ml;LNVBuVQ>? NXLKS3lDPzKq MX7zeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ NF;ZRYozOzN7NUi3OS=>
Hela  MlnySpVv[3Srb36gRZN{[Xl? MW[1cW0> NYDEU4lOOjSq MWnpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 MUOyN|M6PTZ5OR?=
MCF-7  M1nsWGZ2dmO2aX;uJGF{e2G7 MnTDOY1O MlHQNlRp NIPZSYRqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NXqzWXFzOjN|OUW2O|k>
HUVECs M2O5UGZ2dmO2aX;uJGF{e2G7 MWSzcW0> NVXEXItLOjSq MXTicI9kc3NidHjlJJBzd3SnY4TpeoUh\W[oZXP0JI9nKHKnc4\ldoF1em:uIHL5JIlvcGmkaYTpcoch[XW2b4DoZYd6 NEfMfmwzOzN3OEmyPC=>
T24 NY\PSoQzTnWwY4Tpc44hSXO|YYm= NV22XYQ{OTCvTR?= MWOxbC=> MnvrdoVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= NHXEZ40zOzN3NEC4NC=>
U251MG  MV;GeY5kfGmxbjDBd5NigQ>? M2TBT|NuVQ>? NYnBfXdHOWh? MVzzeZBxemW|c3XzJGxEOy2LSTDwdo91\WmwIHX4dJJme3Orb36= NHLFVpMzOzN|OE[xPC=>
GTL-16  NHjjWGRCeG:ydH;zbZMhSXO|YYm= MoTnOY1O MViyOIg> M1HFV5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYOgZ49ueGG{ZXSgeI8h[2WubIOgeJJm[XSnZDD3bZRpKE2HVDDpcohq[mm2b4Lz NIfLToIzOzNzM{S5NC=>
T-47D M{DYW2Z2dmO2aX;uJGF{e2G7 NXzZ[VRuOTCvTR?= M2q5fVJp MoPQbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? NHT6S4czOzNyMECyOi=>
PaCa44 Mlm5RZBweHSxc3nzJGF{e2G7 MlPVNk42dU1? MoW0NYg> NHjSSmpz\WS3Y3XzxsBo\W6rcHnuMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NW\oTmJiOjNzMkSxNVI>
MDA-MB231 NVzCSo82TnWwY4Tpc44hSXO|YYm= NELabW82dU1? NIf2fXUycA>? NGfxb|RqdmO{ZXHz[ZMhemW|dnXyZZRzd2xvbXXkbYF1\WRiY3HzdIF{\SCjY4TpeoF1cW:wIHHu[EBk\WyuIHTlZZRp NEDuXWEzOzB6OEi1NC=>
HeLa MnnQRZBweHSxc3nzJGF{e2G7 Mn;vNVBuVQ>? M3n2W|Jp M1TuXIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdH3lcpQhf2m2aDDQSWk> MkH5NlMxODBzM{W=
SK-HEP-1 M4TBVWFxd3C2b4Ppd{BCe3OjeR?= MnLuNVBuVQ>? MVSxbC=> MY\wdo91\WO2czDh[4FqdnO2IHH1eI9xcGGpeTDhcoQhcW6mdXPld{BieG:ydH;zbZMhcW5iYoXmZYxqdi22cnXheIVlKGOnbHzz MnPqNlI5PTh4NEm=
HepG2 MUDBdI9xfG:|aYOgRZN{[Xl? NIq0PJU{dU1? NX[0[WdPPWh? MmXOdoVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> NITrbZczOjh|NkW5OS=>
MCF-7  Ml3wSpVv[3Srb36gRZN{[Xl? NXvKfmF7Om2P MYqyOIg> MWnpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi NWDJTXp7OjR7N{C2O|Y>
MDA-MB-231 NHfwc|dHfW6ldHnvckBCe3OjeR?= NInIUZgzdU1? Mkf6NlRp Moj4bY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MW[yOFk4ODZ5Nh?=
MCF-7  M4HBWWZ2dmO2aX;uJGF{e2G7 MnPlNo1O M3f4fFQ5cA>? NH6yNXpxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NUTiUoVxOjR7N{C2O|Y>
MDA-MB-231 MXXGeY5kfGmxbjDBd5NigQ>? M16xRlJuVQ>? MnHkOFhp M4\CXpBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? M1;TZlI1QTdyNke2
PANC-1  M37zdGFxd3C2b4Ppd{BCe3OjeR?= MUixcW0> NX:zWGdZPDiq NFO2b|BFVVOR MUnlcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MUGyOFg1OjF3OB?=
MDA-MB 231 Ml7XRZBweHSxc3nzJGF{e2G7 NXPLNlVvPW2P NYTMOWM5OC53aB?= MVztc4R2dGG2ZYOgWI9kd22rbtMuxsBqdmS3Y3XkJIFxd3C2b4Ppdy=> MWOyOFg{ODd6MR?=
Microglia  MV;BdI9xfG:|aYOgRZN{[Xl? NUDl[5VwPW2P MnnDNlRp Mnju[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo M4TYV|I1QDF6NkCx
A2780cp MU\BdI9xfG:|aYOgRZN{[Xl? MVWyMlVuVQ>? M{XHZVFp NGjPXldl\Eh{Tx?= NYjQSVRv\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NX2wZ49SOjR6MUe5OFY>
HepG2 NF\id|dHfW6ldHnvckBCe3OjeR?= M4fQbVVuVQ>? M17GT|Rp M4i2PIlv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?= NH7FbXgzPDdzM{W4Oy=>
U2OS MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:xNI1O M{HJdVI1cA>? MVrpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> NHXIfIczPDZ|OUCxNy=>
HCT116 NYHIbG81SXCxcITvd4l{KEG|c3H5 NYPoZlQ3PW2P Ml:1NlRp MlnkSG1UVw>? M4jwOYVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NInPO|EzPDZ{NkWyNi=>
MCF-7  NHe1VIpCeG:ydH;zbZMhSXO|YYm= NFHMd|IxNjGvTR?= MWq2bC=> M1j4TYVvcGGwY3XzJJNqenSrbn;sMYlv\HWlZXSgZZBweHSxc3nz MUCyNlc2OTl6OR?=
PC-3  MVLBdI9xfG:|aYOgRZN{[Xl? NWX1flVPOm2P NH;Sc5kzcA>? MoW3bY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? NGTnelUzOjd2NUW4NC=>
U251  M4DOdGFxd3C2b4Ppd{BCe3OjeR?= NWCwOoFHPW2P MUeyOIg> MYjpcoNz\WG|ZYOgV|EucW6mdXPl[EBk\WyuIHTlZZRp NFyyXZIzOjV5OUe4PC=>
HeLa  MnzORZBweHSxc3nzJGF{e2G7 MmfaOY1O MYKyOIg> NWLkb4NQcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBk\WyuIHTlZZRp MmXoNlI2PDVzMki=
A549 NHnJSXVHfW6ldHnvckBCe3OjeR?= MWiwMlFuVQ>? MnixNlRp NIjkNI1{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp MlPDNlI1PjZ7NkC=
pDCs M1\FWWZ2dmO2aX;uJGF{e2G7 NFPXXFIyOG2P MYmwMlVp M{G1SuKhemWmdXPld{B1cGViaX7keYN1cW:wIH;mJGlHVi4QsTDifUB{e1KQQUSw NVHQ[Y5{OjJ|OU[1PVk>
BGC-823 MVHGeY5kfGmxbjDBd5NigQ>? NGHCb2E2dU1? MlfFNog> M4DGV4lvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> MoTXNlI{OjJzNUK=
U937 MYXGeY5kfGmxbjDBd5NigQ>? NWnVb2diOm2P M{TZRVEzcA>? M4nrSIRm[3KnYYPld{B1cGViYYX0c5Bp[We7IILheIlwyqB? MoTDNlIyPTVzNUC=
Marc-145 MYXGeY5kfGmxbjDBd5NigQ>? NIXHWJk2dU1? MYWxNk8zPC9|Nni= NVOyclB6emWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u NUnPR2gyOjJzMUm5NFA>
HBx  NYj5[4hzSXCxcITvd4l{KEG|c3H5 Mm\HNVBuVQ>? NUXjRYp6PDiq MX3EUXNQ NVjqdmtJcW6lcnXhd4V{KGOnbHyg[IVifGh? MkHiNlIxOjByN{i=
MCF-7 MoLNSpVv[3Srb36gRZN{[Xl? NFLJeogyOG2P M{jDWlQ5cA>? M{HSboJtd2OtczDheZRweGijZ4mgbY5lfWOnZDDifUBjd3K2ZYrvcYlj NHewNYkzOTl|MUmzOy=>
RMPI8226  MV;GeY5kfGmxbjDBd5NigQ>? MW[1cW0> MnHVNYg> M3zpdJN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? M2\HcVIyQTF3NkKw
PC12/TetOn MVHGeY5kfGmxbjDBd5NigQ>? NVHqeoFZOC5zL{HtUS=> M37icFE5cA>? M{m1doxm[WS|IITvJO6yNXO7bjjXWEkh[WOldX31cIF1cW:wLDD0c5hq[2m2eTygZY5lKG:uaXfvcYVzKG[xcn3heIlwdsLi MoXaNlE6ODZ4NUm=
HeLa  MVnDfZRwfG:6aXPpeJkhSXO|YYm= MX:ycW0> M2W5dlI1cA>? MXfpcohq[mm2ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kB{cWyrYnnubY4hfG9iSHXMZUBk\Wyucz6= MlrFNlE5PzV|OEW=
Jurkat MkjrSpVv[3Srb36gRZN{[Xl? M2PLN|ExdU1? NWDzUFdLOWh? NISyXoxl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MYeyNVg3PDB|Nx?=
K562 NUfTTWd5TnWwY4Tpc44hSXO|YYm= NWjiS3FIOTCvTR?= MkLTNYg> M3vGdYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MX6yNVg3PDB|Nx?=
Nara-H NEjGOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPYVpJFPW2P Mn61OFhp MWHlcohidmOnczD0[Y1{cXKxbHnteZNu\WSrYYTl[EB{fXCycnXzd4lwdiCxZjDOZZJiNUhiY3XscEBxem:uaX\ldoF1cW:w M1PJTVIyQDB3MEOz
HUVECs M1\JSmZ2dmO2aX;uJGF{e2G7 Ml;3NVBuVQ>? MmLKNE42cA>? NYrXN2FM\GWlcnXhd4V{KHSqZTDBS2UuSlODaX7keYNm\CCjdYTvdIhi\3libHX2[S=> M4LJVVIyPDZ6NUmy
HepG2 MU\BdI9xfG:|aYOgRZN{[Xl? MUeycW0> NIH1XIUycA>? NFew[2dmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHTlZZRp MnThNlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID